Kheir, A. et al. 2025. Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab. Acta Oncologica. 64, (Oct. 2025), 1355–1364. DOI:https://doi.org/10.2340/1651-226X.2025.44533.